Literature DB >> 27702752

Emerging data on androgen receptor splice variants in prostate cancer.

Subing Cao1,2, Yang Zhan1,2, Yan Dong3,2.   

Abstract

Androgen receptor splice variants are alternatively spliced variants of androgen receptor, which are C-terminally truncated and lack the canonical ligand-binding domain. Accumulating evidence has indicated a significant role of androgen receptor splice variants in mediating resistance of castration-resistant prostate cancer to current therapies and in predicting therapeutic responses. As such, there is an urgent need to target androgen receptor splicing variants for more effective treatment of castration-resistant prostate cancer. Identification of precise and critical targeting points to deactivate androgen receptor splicing variants relies on a deep understanding of how they are generated and the mechanisms of their action. In this review, we will focus on the emerging data on their generation, clinical significance and mechanisms of action as well as the therapeutic influence of these findings.
© 2016 Society for Endocrinology.

Entities:  

Keywords:  androgen receptor; cofactors; dimerization; prostate cancer; splice variant

Mesh:

Substances:

Year:  2016        PMID: 27702752      PMCID: PMC5107136          DOI: 10.1530/ERC-16-0298

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  115 in total

1.  Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.

Authors:  Siu Chiu Chan; Yingming Li; Scott M Dehm
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

2.  Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.

Authors:  Xi Yang; Zhiyong Guo; Feng Sun; Wei Li; Alan Alfano; Hermela Shimelis; Mingyuan Chen; Angela M H Brodie; Hegang Chen; Zhen Xiao; Timothy D Veenstra; Yun Qiu
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

3.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

4.  Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.

Authors:  Mengqian Chen; Michael A Feuerstein; Elina Levina; Prateek S Baghel; Richard D Carkner; Matthew J Tanner; Michael Shtutman; Francis Vacherot; Stéphane Terry; Alexandre de la Taille; Ralph Buttyan
Journal:  Mol Cancer       Date:  2010-04-26       Impact factor: 27.401

5.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

6.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Authors:  Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

7.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

Authors:  Eleni Efstathiou; Mark Titus; Sijin Wen; Anh Hoang; Maria Karlou; Robynne Ashe; Shi Ming Tu; Ana Aparicio; Patricia Troncoso; James Mohler; Christopher J Logothetis
Journal:  Eur Urol       Date:  2014-05-29       Impact factor: 20.096

8.  Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.

Authors:  Guanyi Zhang; Xichun Liu; Jianzhuo Li; Elisa Ledet; Xavier Alvarez; Yanfeng Qi; Xueqi Fu; Oliver Sartor; Yan Dong; Haitao Zhang
Journal:  Oncotarget       Date:  2015-09-15

9.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.

Authors:  David T Miyamoto; Yu Zheng; Ben S Wittner; Richard J Lee; Huili Zhu; Katherine T Broderick; Rushil Desai; Douglas B Fox; Brian W Brannigan; Julie Trautwein; Kshitij S Arora; Niyati Desai; Douglas M Dahl; Lecia V Sequist; Matthew R Smith; Ravi Kapur; Chin-Lee Wu; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

10.  Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.

Authors:  Friedemann Zengerling; Wolfgang Streicher; Andres J Schrader; Mark Schrader; Bianca Nitzsche; Marcus V Cronauer; Michael Höpfner
Journal:  Int J Mol Sci       Date:  2012-09-14       Impact factor: 6.208

View more
  23 in total

Review 1.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

Review 2.  Allosteric alterations in the androgen receptor and activity in prostate cancer.

Authors:  Takuma Uo; Stephen R Plymate; Cynthia C Sprenger
Journal:  Endocr Relat Cancer       Date:  2017-09       Impact factor: 5.678

Review 3.  Clinical and Novel Biomarkers in the Management of Prostate Cancer.

Authors:  Cristóbal Sanhueza; Manish Kohli
Journal:  Curr Treat Options Oncol       Date:  2018-02-08

4.  Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity.

Authors:  Wooi F Lim; Mitra Forouhan; Thomas C Roberts; Jesse Dabney; Ruth Ellerington; Alfina A Speciale; Raquel Manzano; Maria Lieto; Gavinda Sangha; Subhashis Banerjee; Mariana Conceição; Lara Cravo; Annabelle Biscans; Loïc Roux; Naemeh Pourshafie; Christopher Grunseich; Stephanie Duguez; Anastasia Khvorova; Maria Pennuto; Constanza J Cortes; Albert R La Spada; Kenneth H Fischbeck; Matthew J A Wood; Carlo Rinaldi
Journal:  Sci Adv       Date:  2021-08-20       Impact factor: 14.136

5.  Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy.

Authors:  Tianfang Ma; Shanshan Bai; Yanfeng Qi; Yang Zhan; Nathan Ungerleider; Derek Y Zhang; Taavi Neklesa; Eva Corey; Scott M Dehm; Kun Zhang; Erik K Flemington; Yan Dong
Journal:  Cancer Lett       Date:  2021-02-06       Impact factor: 8.679

Review 6.  Clinical relevance of androgen receptor alterations in prostate cancer.

Authors:  Emma Jernberg; Anders Bergh; Pernilla Wikström
Journal:  Endocr Connect       Date:  2017-11       Impact factor: 3.335

7.  A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer.

Authors:  Chin-Hsien Tsai; Sheue-Fen Tzeng; Shih-Chuan Hsieh; Chia-Jui Tsai; Yu-Chih Yang; Mong-Hsun Tsai; Pei-Wen Hsiao
Journal:  Front Pharmacol       Date:  2017-10-10       Impact factor: 5.810

8.  Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model.

Authors:  David J McCarty; Weiliang Huang; Maureen A Kane; Puranik Purushottamachar; Lalji K Gediya; Vincent C O Njar
Journal:  Oncotarget       Date:  2017-08-01

9.  Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.

Authors:  Amro Aboukameel; Irfana Muqbil; Erkan Baloglu; William Senapedis; Yosef Landesman; Christian Argueta; Michael Kauffman; Hua Chang; Trinayan Kashyap; Sharon Shacham; Jasper E Neggers; Dirk Daelemans; Elisabeth I Heath; Asfar S Azmi
Journal:  Oncotarget       Date:  2018-10-19

Review 10.  Impact of taxanes on androgen receptor signaling.

Authors:  Shanshan Bai; Bryan Y Zhang; Yan Dong
Journal:  Asian J Androl       Date:  2019 May-Jun       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.